Clinical Trial Update: c-Met Second-Line Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for a c-Met targeted approach in second-line hepatocellular carcinoma has completed enrollment with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-08-09